The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma

“…Kornélia Kajȧry and Dr. Zsuzsa Molnár publish their research article entitled "The role of 18F-FDG PET/CT before and after the treatment of multiple myeloma: Our clinical experience" in this issue of AMOR (page [20][21][22][23][24][25][26][27][28][29][30] ung cancer is responsible for millions of death worldwide each year and it is the second most common cancer in both men and women. According to the American Cancer Society, lung cancer is responsible for about 1 in 4 cancer deaths and 14% of all new cases.…”

Section: Dr Kajȧry With a Patient (Photo Credits: Dr Kornélia Kajȧry)mentioning

confidence: 99%

“…positive MRI result had a median time of progression to symptomatic disease of 13 to 15 months and a 2-year probability of progression of approximately 70% [27,28] . It is important to note that FDG PET/CT is consistently unable to detect focal and/or diffuse marrow abnormalities in patients with MGUS and smoldering MM [14] .…”

mentioning

confidence: 99%

AMOR Vol. 3, Issue 1, February 2017

Wang¹

2017

Adv Mod Oncol Res

View full text Add to dashboard Cite

show abstract

“…Similar to MGUS, SMM is characterized by the absence of CRAB features. Importantly, SMM patients with a BM plasma cell percentage ≥60%, FLC ratio ≥100, or >1 lesion on MRI (either with whole-body MRI [15] or axial MRI [16]) have approximately an 80% risk of developing CRAB features within 2 years [17,18]. Using these biomarkers of malignancy, a small subgroup of ultra-high-risk SMM patients is identified, which according to the revised IMWG criteria are now considered to have MM requiring therapy irrespective of the presence or absence of CRAB features.…”

Section: Smoldering Multiple Myelomamentioning

confidence: 99%

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

Donk

Mutis

Poddighe

et al. 2016

Int J Lab Hematology

View full text Add to dashboard Cite

KeywordsMonoclonal gammopathy of undetermined significance, smoldering multiple myeloma, multiple myeloma, diagnosis, management, treatment S U M M A RYMonoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders. IgG and IgA MGUS are precursor conditions of multiple myeloma (MM), whereas light-chain MGUS is a precursor condition of light-chain MM. Smoldering MM (SMM) is a precursor condition with higher tumor burden and higher risk of progression to symptomatic MM compared to MGUS. Assessment of the risk of progression of patients with asymptomatic monoclonal gammopathies is based on various factors including clonal burden, as well as biological characteristics, such as cytogenetic abnormalities and light-chain production. Several models have been constructed that are useful in daily practice for predicting risk of progression of MGUS or SMM. Importantly, the plasma cell clone may occasionally be responsible for severe organ damage through the production of a M-protein which deposits in tissues or has autoantibody activity. These disorders are rare and often require therapy directed at eradication of the underlying clone. Importantly, recent studies have shown that asymptomatic patients with a bone marrow plasma cell percentage ≥60%, free light-chain ratio ≥100, or >1 focal lesion on MRI (myeloma-defining events) have a 80% risk of developing symptomatic MM within 2 years. These patients are now considered to have MM requiring therapy, similar to patients with symptomatic disease. In this review, we provide an overview of the new diagnostic criteria of the monoclonal gammopathies and discuss risk of progression to active MM. We also provide recommendations for the management of patients with MGUS and SMM including risk-adapted follow-up.

show abstract

The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma

Cited by 123 publications

References 13 publications

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

AMOR Vol. 3, Issue 1, February 2017

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

Contact Info

Product

Resources

About